Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Back to 60 cents

<< Previous

Bullboard Posts

Next >>

Comment by davgroon Feb 24, 2023 3:20pm

90 Views

Post# 35304189

RE:Back to 60 cents

It was one buyer at TD who placed a large order at the bid. Price will not be maintained and will drop back to mid C$0.50s very quickly.

You understand nothing about trading. While you try to flip pennies with low volume stocks like ATE I made a killing today on HEXO swing trades. Add to the fact that last week I made $13K profit in HEXO in 4 days swing trading. You probably don't have $13K in your whole investment portfolio. You truly are just a pathetic troll.

Have a good weekend, while you are having a Happy Meal at McDonald's tonight I will be celebrating an excellent trading day with some fine 25 year old single malt scotch.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects